Search

• ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1

  Media

  Results illustrate ViiV Healthcare’s pipeline is generating multiple options for the development of new ultra long-acting HIV regimens.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-showcases-leadership-in-long-acting-injectables-innovation-at-croi-2025-with-data-on-insti-and-highly-potent-capsid-inhibitor-against-hiv-1/

  First published: 11 March 2025

• ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV

  Media

  Maturation inhibitors are a class of antiretroviral medicines that target the late stage of the HIV viral life cycle.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-proof-of-concept-findings-for-gsk3640254-a-novel-investigational-maturation-inhibitor-for-the-treatment-of-hiv/

  First published: 09 March 2021

• GSK receives marketing authorisation from the European Commission for additional Revolade™

  Media

  GSK announced that the EC has granted Revolade™ as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection.

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-from-the-european-commission-for-additional-revolade/

  First published: 24 September 2013

• The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®

  Media

  The UK is now one of the leading countries in stockpiling antivirals for treating infected individuals in event of an influenza pandemic

  https://www.gsk.com/en-gb/media/press-releases/the-uk-government-signs-influenza-pandemic-contract-with-glaxosmithkline-for-relenza/

  First published: 28 January 2009

• GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection

  Media

  GSK announced a positive opinion from EMA's CHMP recommending marketing authorisation for Revolade™ (eltrombopag).

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-revolade-in-thrombocytopenia-associated-with-chronic-hepatitis-c-infection/

  First published: 26 July 2013

• 

  Unlocking the power of the immune system to get ahead of hepatitis B

  Behind the science magazine

  GSK’s innovation team have developed a longer-lasting, more effective treatment for this global health problem

  https://www.gsk.com/en-gb/behind-the-science-magazine/unlocking-the-power-of-the-immune-system-to-get-ahead-of-hepatitis-b/

  First published: 22 June 2022

• 

  Tony Wood

  Company

  Tony was appointed Chief Scientific Officer designate on 19 January 2022 and became Chief Scientific Officer on 1 August 2022.

  https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/tony-wood/

  First published: 12 July 2024

• GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries

  Media

  GSK today announced that it has signed an agreement with WHO to donate 50 million doses of its influenza vaccine.

  https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-with-the-who-to-donate-50-million-doses-of-pandemic-h1n1-vaccine-for-distribution-to-developing-countries/

  First published: 09 November 2009

• ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

  Media

  ATLAS-2M study met its primary endpoint.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-phase-iii-study-results-of-investigational-long-acting-injectable-hiv-treatment-regimen-administered-every-two-months/

  First published: 22 August 2019

• GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B

  Media

  Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B (CHB)

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b/

  First published: 12 February 2024